Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Common Equity (2020 - 2025)

RxSight's Common Equity history spans 6 years, with the latest figure at $275.7 million for Q4 2025.

  • For Q4 2025, Common Equity fell 1.98% year-over-year to $275.7 million; the TTM value through Dec 2025 reached $275.7 million, down 1.98%, while the annual FY2025 figure was $275.7 million, 1.98% down from the prior year.
  • Common Equity reached $275.7 million in Q4 2025 per RXST's latest filing, roughly flat from $276.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $281.2 million in Q4 2024 to a low of -$313.4 million in Q2 2021.
  • Average Common Equity over 5 years is $141.2 million, with a median of $158.8 million recorded in 2023.
  • The largest YoY upside for Common Equity was 140.8% in 2022 against a maximum downside of 36.41% in 2022.
  • A 5-year view of Common Equity shows it stood at $138.2 million in 2021, then tumbled by 34.97% to $89.9 million in 2022, then soared by 78.37% to $160.4 million in 2023, then soared by 75.38% to $281.2 million in 2024, then fell by 1.98% to $275.7 million in 2025.
  • Per Business Quant, the three most recent readings for RXST's Common Equity are $275.7 million (Q4 2025), $276.0 million (Q3 2025), and $278.0 million (Q2 2025).